PolyPid Q2 FY26 net loss narrows 22% to $7.8 million
Reuters2026/08/12 11:32- PolyPid posted a Q2 net loss of $7.8 million, narrowing from a $10 million loss a year earlier; loss per share improved to $(0.35).
- R&D spending edged down to $6.1 million, while G&A expenses fell to $1.3 million on lower non-cash PSU vesting charges.
- Cash and cash equivalents totaled $6.6 million at June 30, down from $12.9 million at Dec. 31, excluding $30 million from Azurity.
- FDA accepted the D-PLEX100 NDA with Priority Review; PDUFA goal date set for Nov. 28, 2026, about one quarter earlier.
- Azurity deal triggered $30 million in upfront and near-term milestones; agreement includes up to about $320 million total milestones, royalties up to mid-20%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Zcash Price Targets $1800 as Privacy Demand Fuels Rally
Citadel Securities sounds the alarm: September “curse” combined with cheap options, short-term risk-reward in US stocks deteriorates sharply
September is typically the worst-performing month for U.S. stocks, with the S&P 500's average monthly return at its lowest point of the year. Currently, option prices are also at their cheapest level of the year—combining these two factors makes the risk-reward ratio of buying downside protection particularly attractive.
Arista Networks 10% owner Andreas Bechtolsheim sells USD 60.02 million in common shares
Crypto prices
More
